This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miknyoczki, S. J. Articles by Ruggeri, B. A. Search for Related Content PubMed PubMed Citation Articles by Miknyoczki, S. J. Articles by Ruggeri, B. A.

The Trk Tyrosine Kinase Inhibitor CEP-701 (KT-5555) Exhibits Significant Antitumor Efficacy in Preclinical Xenograft Modelsof Human Pancreatic Ductal Adenocarcinoma¹

Department of Oncology, Cephalon, Inc., West Chester, Pennsylvania 19380 [S. J. M., H. C., C. A. D., B. A. R.], and Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [A. K-S.]

The aggressive behavior and poor prognosis of pancreatic ductal adenocarcinoma (PDAC) is associated with an increased expression of many growth factors and their cognate receptors. We have previously demonstrated the aberrant expression of the Trk receptors (Trks A, B, and C), enhanced tumor stromal expression of neurotrophins in primary PDAC specimens and human PDAC-derived cell lines, and a dose-dependent biological response of PDAC cells (in vitro invasiveness) to selective neurotrophins (Miknyoczki, S. J., et al., Int. J. Cancer, 81: 417–427, 1999). On the basis of these data, we have evaluated the therapeutic potential of inhibiting neurotrophin-Trk interactions using a selective and potent Trk tyrosine kinase inhibitor (CEP-701) in several preclinical models of human PDAC. CEP-701 is currently approved for clinical trials within the United States We demonstrate that CEP-701 administration at 10 mg/kg s.c. b.i.d. 5 days a week for 21–28 days inhibited tumor growth in a statistically significant manner in Panc-1, AsPc-1, BxPc-3, Colo 357, and MiaPaCa2 s.c. xenografts in athymic nude mice compared with vehicle-treated controls. Reductions in tumor growth volume of 50–70% relative to vehicle-treated controls were observed in xenografts responsive to CEP-701 administration. Significant reductions of in vivo PDAC tumor invasiveness were likewise observed in four of six CEP-701-treated rat tracheal xenografts implanted s.c. in athymic nude mice. The antitumor efficacy of CEP-701 was observed in the absence of pronounced morbidity or toxicity in vivo. Taken together, these data suggest that CEP-701 may be effective as a potential therapeutic agent in the treatment or management of PDAC.

This article has been cited by other articles:

				W. Jin, B.-C. Kim, C. Tognon, H.-J. Lee, S. Patel, C. L. Lannon, J. M. Maris, T. J. Triche, P. H. B. Sorensen, and S.-J. Kim The ETV6-NTRK3 chimeric tyrosine kinase suppresses TGF-{beta} signaling by inactivating the TGF-{beta} type II receptor PNAS, November 8, 2005; 102(45): 16239 - 16244. [Abstract] [Full Text] [PDF]

				S. J. Miknyoczki, W. Wan, H. Chang, P. Dobrzanski, B. A. Ruggeri, C. A. Dionne, and K. Buchkovich The Neurotrophin-Trk Receptor Axes Are Critical for the Growth and Progression of Human Prostatic Carcinoma and Pancreatic Ductal Adenocarcinoma Xenografts in Nude Mice Clin. Cancer Res., June 1, 2002; 8(6): 1924 - 1931. [Abstract] [Full Text] [PDF]

				A. T. Weeraratna, S. L. Dalrymple, J. C. Lamb, S. R. Denmeade, S. Miknyoczki, C. A. Dionne, and J. T. Isaacs Pan-trk Inhibition Decreases Metastasis and Enhances Host Survival in Experimental Models as a Result of Its Selective Induction of Apoptosis of Prostate Cancer Cells Clin. Cancer Res., August 1, 2001; 7(8): 2237 - 2245. [Abstract] [Full Text] [PDF]

				S. Kern, R. Hruban, M. A. Hollingsworth, R. Brand, T. E. Adrian, E. Jaffee, and M. A. Tempero A White Paper: The Product of a Pancreas Cancer Think Tank Cancer Res., June 1, 2001; 61(12): 4923 - 4932. [Full Text] [PDF]

				Z.-w. Zhu, H. Friess, L. Wang, T. Bogardus, M. Korc, J. Kleeff, and M. W. Büchler Nerve Growth Factor Exerts Differential Effects on the Growth of Human Pancreatic Cancer Cells Clin. Cancer Res., January 1, 2001; 7(1): 105 - 112. [Abstract] [Full Text]

				J. Turkson, D. Ryan, J. S. Kim, Y. Zhang, Z. Chen, E. Haura, A. Laudano, S. Sebti, A. D. Hamilton, and R. Jove Phosphotyrosyl Peptides Block Stat3-mediated DNA Binding Activity, Gene Regulation, and Cell Transformation J. Biol. Chem., November 21, 2001; 276(48): 45443 - 45455. [Abstract] [Full Text] [PDF]